Our Services
Medical Information
Helpful Resources
Published on: 9/28/2026
Indomethacin is a prescription NSAID used to relieve acute gout pain, typically dosed at 50 mg three times daily with food until symptoms ease, then tapered quickly, with most flares treated for about 3 to 7 days. Starting treatment within the first 24 hours of a flare and never exceeding your prescriber's daily limit are key to fast relief and lower risk. Dosing may need to be lowered or avoided entirely if you have kidney disease, stomach ulcers, heart failure, or take blood thinners, and several other factors can change what is safe for you. See below to understand more about timing, tapering, side effects, and alternatives before your next dose.
Because gout pain can mimic infections, injuries, and other types of arthritis that require very different treatment, confirming what is actually driving your symptoms matters before reaching for an NSAID, so take a free, instant, online symptom check to clarify your likely cause and map out smart next steps with your clinician.
Last reviewed for medical accuracy: 09/28/2026
Gout is a form of arthritis caused by the buildup of uric acid crystals in joints, leading to sudden, intense pain and swelling. One of the most commonly prescribed nonsteroidal anti-inflammatory drugs (NSAIDs) for treating gout flares is indomethacin. This guide covers how indomethacin for gout is dosed during an acute attack, along with safety tips and when to seek medical advice.
Indomethacin is an NSAID that reduces inflammation and pain by blocking cyclooxygenase enzymes (COX-1 and COX-2). Unlike some other NSAIDs, indomethacin has strong anti-inflammatory effects, making it particularly effective for severe gout flares.
Key points:
Indomethacin is often preferred for gout because:
However, like all NSAIDs, it carries risks—especially for the stomach, kidneys, and cardiovascular system.
Dosing should always be personalized by a healthcare professional. The following is a general guide based on published clinical recommendations:
Initial Phase (Days 1–2)
Tapering Phase (Days 3–7)
Extended-Release Option
Before and during treatment with indomethacin for gout, monitoring can help reduce risks:
While many tolerate indomethacin well for short courses, watch for:
If you experience severe stomach pain, black/tarry stools, sudden weight gain, chest pain, or shortness of breath, stop the medication and seek medical care immediately.
Avoid indomethacin if you have:
Use caution when combining with:
Always tell your doctor about all prescription, over-the-counter, and herbal products you’re taking.
If you’re unsure whether your symptoms match a gout flare or if they feel unusually severe, you might try a free, online symptom check, using the doctor approved Ubie Symptom Checker. It can help you decide if you should seek medical care right away.
Even with prompt treatment, some situations require immediate professional care:
Always speak to a doctor about anything that could be life-threatening or serious.
Indomethacin for gout is a well-established choice to rapidly reduce pain and inflammation during flares. Standard dosing starts at 50 mg three times daily for 1–2 days, tapering over the next 5–7 days. Take it with food, watch for side effects, and monitor kidney, liver, and gastrointestinal health. Avoid contraindicated medications and conditions, and always follow your doctor’s personalized plan.
If you ever feel uncertain about your symptoms or the next steps, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. And remember, for any life-threatening or serious concerns, speak to a doctor right away.
(References)
* HART FD, BOARDMAN PL. INDOMETHACIN: A NEW NON-STEROID ANTI-INFLAMMATORY AGENT. Br Med J. 1963 Oct 19;2(5363):965-70. doi: 10.1136/bmj.2.5363.965. PMID: 14056924; PMCID: PMC1873102.
* HART FD, BOARDMAN PL. INDOMETHACIN. Practitioner. 1964 Jun;192:828-32. PMID: 14168832.
* REAH TG. GOUT. Practitioner. 1964 Sep;193:306-14. PMID: 14213731.
* MICHOTTE LJ, WAUTERS M. CLINICAL TEST OF INDOMETHACIN. Acta Rheumatol Scand. 1964;10:273-80. doi: 10.3109/rhe1.1964.10.issue-1-4.31. PMID: 14237384.
* MICHOTTE LJ, WANTERS M. [CLINICAL TRIAL OF INDOMETHACIN]. Rhumatologie. 1964 Nov;16:447-51. PMID: 14240280.
* ROBINSON RG. INDOMETHACIN IN RHEUMATIC DISEASE: A CLINICAL ASSESSMENT. Med J Aust. 1965 Feb 20;1(8):266-9. doi: 10.5694/j.1326-5377.1965.tb71619.x. PMID: 14261368.
* BOARDMAN PL, HARTDUDLEY F. 208.--INDOMETHACIN IN THE TREATMENT OF ACUTE GOUT. Practitioner. 1965 Apr;194:560-5. PMID: 14273208.
* HOLT LP, HAWKINS CF. INDOMETHACIN: STUDIES OF ABSORPTION AND OF THE USE OF INDOMETHACIN SUPPOSITORIES. Br Med J. 1965 May 22;1(5446):1354-6. doi: 10.1136/bmj.1.5446.1354. PMID: 14278842; PMCID: PMC2165800.
* EGELIUS N. INDOMETHACIN: A NEW ANTI-RHEUMATIC DRUG. Acta Rheumatol Scand. 1965;11:35-9. doi: 10.3109/rhe1.1965.11.issue-1-4.06. PMID: 14308109.
* BUCHMANN E. THE ANTIRHEUMATIC EFFECT OF INDOMETHACIN. Acta Rheumatol Scand. 1965;11:40-52. doi: 10.3109/rhe1.1965.11.issue-1-4.07. PMID: 14308110.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.